Posted by Michael Wonder on 20 May 2020
Atomoxetine – further delay in change of funded brand and open access
20 May 2020 - PHARMAC is advising all interested parties that there is a further one-month delay in the listing of a new funded brand of atomoxetine and removal of the current funding restrictions.
The following reflects the most up-to-date information.
The listing of the Generic Partners’ brand of atomoxetine capsules (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg) has been further delayed and will now be listed from 1 July 2020. The restrictions will be removed from atomoxetine from that date.
The current funded brand, Strattera, will remain listed until 1 December 2020.
